A European Multicientre Study on the Analytical Performance of the VERIS HBV Assay

Hepatitis B virus (HBV) is estimated to affect 400 million people worldwide, with approximately 240 million chronically infected [1 –3]. Individuals with chronic HBV are at increased risk of developing cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC) [1,2,4–6] and elevations in HBV DNA viral levels have been shown to be associated with both risk of progression to cirrhosis and risk of HCC [7–10]. Measu rement of HBV viral loads (VL) is an essential part of the management of chronic HBV with regard to treatment start, predicting treatment response, and monitoring treatment resistance.

Source: Journal of Clinical Virology - December 19, 2017 Category: Virology Authors: Patrick Braun, Rafael Delgado, Monica Drago, Diana Fanti, Herv é Fleury, Jacques Izopet, Alessandra Lombardi, Alessandro Mancon, Mª Angeles Marcos, Karine Sauné, Siobhan O'Shea, Alfredo Pérez-Rivilla, John Ramble, Pascale Trimoulet, Jordi Vila, Duncan Source Type: research